Muramyl dipeptide and anti-CD10 monoclonal antibody immunoconjugate enhances anti-leukemia immunity of T lymphocytes.
It is necessary to completely eliminate minimal residual disease (MRD) to cure acute leukemia. Monoclonal antibodies (MAb) have been shown to be effective to eliminate MRD. In this study we aimed to investigate the effect of anti-CD10 MAb conjugated to muramyl dipeptide immunoconjugate (MDP-Ab) on the function of lymphocytes and activated lymphocytes using leukemia xenografts in nude mice as a model. Peripheral blood mononuclear cells were isolated from children with acute lymphoblastic leukemia and induced into dendritic cells (DCs) and lymphocytes. Cytotoxic activity of lymphocytes was detected by LDH release assay. Leukemia xenografts in nude mice were established to assess tumor growth. We found that the killing rate was significantly higher in MDP-Ab group, LPS group and MDP-Ab+LPS group than in control group, and was the highest in MDP-Ab+LPS group. Tumor-bearing mice in MDP-Ab group showed obvious coagulation necrosis. In conclusion, our data suggest that MDP-Ab could effectively prime DCs to improve the anti-tumor immunity of T lymphocytes and inhibit the tumor growth. MDP-Ab may be used as suitable candidate for eliminating residual leukemia cells to prevent relapse.
Department of Pediatric Hematology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Ling-Zhen
LZ
Wang
Department of Pediatrics, Huai'an Maternity and Child Healthcare Hospital Affiliated to Yangzhou University School of Medicine, Huai'an, China.
Li
L
Zhang
Department of Stomatology, Weihai Municipal Hospital, Weihai, China.
Ling-Li
LL
Wang
Department of Pediatric Hematology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Yuan
Y
Lu
Department of Pediatric Hematology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Lei
L
Chen
Department of Pediatric Hematology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Yan
Y
Sun
Department of Hematology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Hong-Guo
HG
Zhao
Department of Pediatric Hematology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Liang
L
Song
Department of Pediatric Hematology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Li-Rong
LR
Sun
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000494:pharmacology*; D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D002470:Cell Survival; D003601:Cytotoxicity Tests, Immunologic; D004195:Disease Models, Animal; D064593:Heterografts; D018796:Immunoconjugates / Q000494:pharmacology; D007155:Immunologic Factors / Q000494:pharmacology*; D007167:Immunotherapy / Q000379:methods; D007938:Leukemia / Q000628:therapy*; D008297:Male; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D018365:Neoplasm, Residual / Q000628:therapy; D015260:Neprilysin / Q000037:antagonists & inhibitors*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D000911:Antibodies, Monoclonal; D018796:Immunoconjugates; D007155:Immunologic Factors; D000119:Acetylmuramyl-Alanyl-Isoglutamine; D015260:Neprilysin
Leukemia; T lymphocytes; anti-CD10 MAb; minimal residual disease; muramyl dipeptide